-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★NoticeShanghai Minhang Biomedical Industry Development Conference and 2021 Life and Health Industry Summit Forum will open in Shanghai ★How to enhance the expansion of T cells and NK cells? Click on the picture to sign up for the conference September 29, 2021 / eMedClub News/---September 28, 2021, Chongqing Precision Bio's innovative CAR-T product C-4-29 cell preparation targeted therapy "CD70 expression" The “positive advanced renal cell carcinoma” indication has been approved by the NMPA clinical trial
.
The CD70 target is an innovative target developed by Chongqing Precision Biotech Co.
, Ltd.
with dual application scenarios of blood and solid tumors.
The C-4-29 cell preparation developed based on this can be used to treat patients with relapsed/refractory multiple Patients with myeloma (MM) or advanced/metastatic renal cell carcinoma (RCC)
.
Its first indication (MM) clinical trial passed the clinical trial implied license of the Center for Drug Evaluation of the National Medical Products Administration on December 10, 2020, and the Phase I clinical study has been initiated; this C-4-29 new adaptation The clinical trial application for the disease belongs to the first category of new therapeutic biological products, and it is the first CAR-T product for renal cell carcinoma solid tumors in China
.
Up to now, Chongqing Precision Bio has obtained the implied license for 5 clinical trials
.
Chongqing Precision Bio-Chongqing Precision Biotechnology Co.
, Ltd.
(hereinafter referred to as the company) was established in 2016.
It is a high-tech enterprise jointly established by a technical team of well-known precision medicine scientist Professor Qian Cheng and a listed company Zhifei Biology (Zhirui Investment).
The company takes gene and cell therapy technologies as the entry point, and is mainly engaged in the development and application of CAR-T cell drugs, and is committed to building a world-class high-end biomedicine research and development institution and pharmaceutical brand enterprise
.
The company has established the Industrial Technology Research Institute, Postdoctoral Workstation and Haizhi Workstation, and has been approved for Chongqing’s new high-end R&D institutions, key laboratories, engineering research centers, engineering technology research centers and other platform qualifications; the company has built 15,700 square meters of domestic top, A complete platform and powerful cell-based drug and production platform, with a highly intelligent production line and quality control platform for plasmid, vector, and cell preparation.
It is a public service platform for biomedical research and development supported by the National Development and Reform Commission and the Ministry of Science and Technology; a collection of companies 20 A number of first-class experts at home and abroad, with 285 employees and more than 220 R&D elite teams; the company already has core technologies in the field of cell therapy through independent research and development, and masters future general-purpose CAR-T, solid tumor CAR-T, etc.
Cutting-edge key technology, applied for 60 core key technology invention patents, obtained 17 domestic and foreign patent authorizations, and carried out special deployment in developed regions such as Europe and the United States; the company has obtained two CAR-T cell first-class new drugs and five indications With implied permission, the clinical registration is progressing smoothly and excellent clinical data has been obtained; the company's layout is applied to more than 10 CARs such as leukemia, lymphoma, myeloma, lymphoma, gastrointestinal cancer, lung cancer, liver cancer, breast cancer, and pancreatic cancer.
The T research and development pipeline has made breakthrough progress.
Renal cell carcinoma has been implied by clinical trials.
Indications such as colorectal cancer have entered the registration clinical application stage.
The world's first breakthrough in the treatment of solid tumors with CAR-T technology is about to be achieved; the company is preparing to build In addition to the production base of new cell drugs in China, it is also actively promoting the transformation and application of globalization strategies.
It has reached agreements with many European and American institutions to establish overseas R&D branches and expand the commercial layout of the international market.
In the next 3 to 5 years, the company will strive to achieve 3 More than one type of new cell drugs are on the market
.
.
The CD70 target is an innovative target developed by Chongqing Precision Biotech Co.
, Ltd.
with dual application scenarios of blood and solid tumors.
The C-4-29 cell preparation developed based on this can be used to treat patients with relapsed/refractory multiple Patients with myeloma (MM) or advanced/metastatic renal cell carcinoma (RCC)
.
Its first indication (MM) clinical trial passed the clinical trial implied license of the Center for Drug Evaluation of the National Medical Products Administration on December 10, 2020, and the Phase I clinical study has been initiated; this C-4-29 new adaptation The clinical trial application for the disease belongs to the first category of new therapeutic biological products, and it is the first CAR-T product for renal cell carcinoma solid tumors in China
.
Up to now, Chongqing Precision Bio has obtained the implied license for 5 clinical trials
.
Chongqing Precision Bio-Chongqing Precision Biotechnology Co.
, Ltd.
(hereinafter referred to as the company) was established in 2016.
It is a high-tech enterprise jointly established by a technical team of well-known precision medicine scientist Professor Qian Cheng and a listed company Zhifei Biology (Zhirui Investment).
The company takes gene and cell therapy technologies as the entry point, and is mainly engaged in the development and application of CAR-T cell drugs, and is committed to building a world-class high-end biomedicine research and development institution and pharmaceutical brand enterprise
.
The company has established the Industrial Technology Research Institute, Postdoctoral Workstation and Haizhi Workstation, and has been approved for Chongqing’s new high-end R&D institutions, key laboratories, engineering research centers, engineering technology research centers and other platform qualifications; the company has built 15,700 square meters of domestic top, A complete platform and powerful cell-based drug and production platform, with a highly intelligent production line and quality control platform for plasmid, vector, and cell preparation.
It is a public service platform for biomedical research and development supported by the National Development and Reform Commission and the Ministry of Science and Technology; a collection of companies 20 A number of first-class experts at home and abroad, with 285 employees and more than 220 R&D elite teams; the company already has core technologies in the field of cell therapy through independent research and development, and masters future general-purpose CAR-T, solid tumor CAR-T, etc.
Cutting-edge key technology, applied for 60 core key technology invention patents, obtained 17 domestic and foreign patent authorizations, and carried out special deployment in developed regions such as Europe and the United States; the company has obtained two CAR-T cell first-class new drugs and five indications With implied permission, the clinical registration is progressing smoothly and excellent clinical data has been obtained; the company's layout is applied to more than 10 CARs such as leukemia, lymphoma, myeloma, lymphoma, gastrointestinal cancer, lung cancer, liver cancer, breast cancer, and pancreatic cancer.
The T research and development pipeline has made breakthrough progress.
Renal cell carcinoma has been implied by clinical trials.
Indications such as colorectal cancer have entered the registration clinical application stage.
The world's first breakthrough in the treatment of solid tumors with CAR-T technology is about to be achieved; the company is preparing to build In addition to the production base of new cell drugs in China, it is also actively promoting the transformation and application of globalization strategies.
It has reached agreements with many European and American institutions to establish overseas R&D branches and expand the commercial layout of the international market.
In the next 3 to 5 years, the company will strive to achieve 3 More than one type of new cell drugs are on the market
.
